Publication:
Prevalence of progression independent of relapse activity and relapse-associated worsening in patients with AQP4-IgG-positive NMOSD

dc.contributor.coauthorPakeeran Siriratnam
dc.contributor.coauthorSaif Huda
dc.contributor.coauthorAnneke Van Der Walt
dc.contributor.coauthorPaul G Sanfilippo
dc.contributor.coauthorSifat Sharmin
dc.contributor.coauthorYi Chao Foong
dc.contributor.coauthorWei Z Yeh
dc.contributor.coauthorChao Zhu
dc.contributor.coauthorSamia J Khoury
dc.contributor.coauthorTunde Csepany
dc.contributor.coauthorBarbara Willekens
dc.contributor.coauthorMasoud Etemadifar
dc.contributor.coauthorSerkan Ozakbas
dc.contributor.coauthorPetra Nytrova
dc.contributor.coauthorAbdullah Al-Asmi
dc.contributor.coauthorCristina M Ramo-Tello
dc.contributor.coauthorGuy Laureys
dc.contributor.coauthorFrancesco Patti
dc.contributor.coauthorDana Horakova
dc.contributor.coauthorMatteo Foschi
dc.contributor.coauthorCavit Boz
dc.contributor.coauthorPamela A Mccombe
dc.contributor.coauthorRecai Turkoglu
dc.contributor.coauthorJeannette Lechner-Scott
dc.contributor.coauthorIzanne Roos
dc.contributor.coauthorTomas Kalincik
dc.contributor.coauthorVilija G Jokubaitis
dc.contributor.coauthorHelmut Butzkueven
dc.contributor.coauthorMastura Monif
dc.contributor.coauthorfor MSBase
dc.contributor.departmentKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAltıntaş, Ayşe
dc.contributor.schoolcollegeinstituteResearch Center
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-03-06T20:59:45Z
dc.date.issued2024
dc.description.abstractOBJECTIVES: In aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), disability accrual is mostly attributed to relapses. This study aimed to assess the prevalence of progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) in AQP4-IgG NMOSD. METHODS: This was a retrospective cohort study of patients with AQP4-IgG NMOSD enrolled in the MSBase international data registry. Patients required a minimum of 3 recorded Expanded Disability Status Scale (EDSS) scores: baseline, event, and a 6-month confirmation score. Presence and absence of relapses between the baseline and event EDSS scores determined RAW and PIRA, respectively. Descriptive statistics were used to present the results. RESULTS: A total of 181 patients followed for a median of 4.5 years (Q1 1.7, Q3 7.8) were included. Most patients were female (88.4%), and the median age at disease onset was 38.1 years. Overall, 4 patients (2.2%) developed 5 incidences of PIRA and 13 patients developed RAW (7.2%). DISCUSSION: This multicenter study highlights that PIRA is very rare in AQP4-IgG NMOSD. Limitations of this study include the sole focus of overall EDSS to measure disability, lack of requirement for a second EDSS score to confirm baseline EDSS, and the absence of magnetic resonance imaging information for all patients.
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.identifier.doi10.1212/WNL.0000000000209940
dc.identifier.issn1526-632X
dc.identifier.issue12
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-85210113292
dc.identifier.urihttps://doi.org/10.1212/WNL.0000000000209940
dc.identifier.urihttps://hdl.handle.net/20.500.14288/27754
dc.identifier.volume103
dc.keywordsAQP4-IgG-positive NMOSD
dc.keywordsNeuromyelitis optica spectrum disorder
dc.keywordsProgression independent of relapse activity (PIRA)
dc.language.isoeng
dc.publisherLippincott Williams and Wilkins
dc.relation.ispartofNeurology
dc.subjectNeurosciences
dc.titlePrevalence of progression independent of relapse activity and relapse-associated worsening in patients with AQP4-IgG-positive NMOSD
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorAltıntaş, Ayşe
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1Research Center
local.publication.orgunit2KUTTAM (Koç University Research Center for Translational Medicine)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublication91bbe15d-017f-446b-b102-ce755523d939
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscovery91bbe15d-017f-446b-b102-ce755523d939
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscoveryd437580f-9309-4ecb-864a-4af58309d287

Files